Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer

Rui Xiong, Hitisha K. Patel, Lauren M. Gutgesell, Jiong Zhao, Loruhama Delgado-Rivera, Thao N.D. Pham, Huiping Zhao, Kathryn Carlson, Teresa Martin, John A. Katzenellenbogen, Terry W. Moore, Debra A. Tonetti, Gregory R.J. Thatcher

Research output: Contribution to journalArticlepeer-review

Abstract

Almost 70% of breast cancers are estrogen receptor α (ERα) positive. Tamoxifen, a selective estrogen receptor modulator (SERM), represents the standard of care for many patients; however, 30-50% develop resistance, underlining the need for alternative therapeutics. Paradoxically, agonists at ERα such as estradiol (E2) have demonstrated clinical efficacy in patients with heavily treated breast cancer, although side effects in gynecological tissues are unacceptable. A drug that selectively mimics the actions of E2 in breast cancer therapy but minimizes estrogenic effects in other tissues is a novel, therapeutic alternative. We hypothesized that a selective human estrogen receptor partial agonist (ShERPA) at ERα would provide such an agent. Novel benzothiophene derivatives with nanomolar potency in breast cancer cell cultures were designed. Several showed partial agonist activity, with potency of 0.8-76 nM, mimicking E2 in inhibiting growth of tamoxifen-resistant breast cancer cell lines. Three ShERPAs were tested and validated in xenograft models of endocrine-independent and tamoxifen-resistant breast cancer, and in contrast to E2, ShERPAs did not cause significant uterine growth.

Original languageEnglish (US)
Pages (from-to)219-237
Number of pages19
JournalJournal of Medicinal Chemistry
Volume59
Issue number1
DOIs
StatePublished - Jan 14 2016

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Fingerprint Dive into the research topics of 'Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer'. Together they form a unique fingerprint.

Cite this